Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease

BackgroundProprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been documented with significantly reduction in LDL cholesterol levels and cardiovascular events. However, evidence regarding the impact of PCSK9 inhibitors on coronary calcification is limited.MethodsEligible patients w...

Full description

Bibliographic Details
Main Authors: Fei Gao, Yue Ping Li, Xiao Teng Ma, Zhi Jian Wang, Dong Mei Shi, Yu Jie Zhou
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
coronary artery disease
coronary calcification
PCSK9 inhibition therapy
alirocumab
statin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.907662/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.907662/full

Similar Items